Randox showcasing NI innovation at Europe’s biggest medical expo
Global biotechnology firm Randox is unveiling its latest, state-of-the-art laboratory technology at one of the biggest medical exhibitions in the world.
Randox, headquartered in County Antrim, is exhibiting at EuroMedLab in Paris, where it is launching its new clinical healthcare analyser; the RX Altona, which will be exported to hospitals, veterinary clinics and teaching laboratories across the globe.
The machine; the latest of a range of equipment designed and manufactured by Randox, is attracting the attention of key international customers, across the world.
Graeme McNeill, Global Sales Manager at Randox says the new analyser has been developed to offer cutting-edge technology and functionality, typically associated with larger instruments, on a small footprint analyser.
“At Randox we have utilised our talents and experience in the life sciences, software development and engineering to create this pioneering technology, building on over a decade of R&D for this particular product range.
“The new RX Altona shines a new light on semi-automated chemistry testing with its touch screen technology and here in Paris, we have had interest from Ministries of Health, leading clinics and research institutes around the world.”
Dr Peter FitzGerald, MD at Randox, says the company is proud to be promoting Northern Ireland’s innovation to an international audience:
“Randox is committed to improving healthcare worldwide and our clinical chemistry analysers are already in place in 120 countries; but this new machine is the next generation in Randox diagnostic capabilities. It will ensure that clinicians get the most reliable and accurate results and more quickly – allowing patients to be treated effectively and efficiently.
“The RX Altona is the epitome of our ambition, our innovation and is indicative of the high-calibre scientific, engineering and software talent we have in the region.”
Randox is also showcasing a new test which is a key predictor for cardio-vascular disease and heart attacks. The test identifies a biomarker in the blood called SPLA2; people with high levels of this biomarker can be three times more likely to suffer a severe coronary event.
EuroMedLab 2015, runs from the 22nd- 24th of June at the Palais de Congrés de Paris.